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ABSTRACT
Interferon regulatory factor 4 (IRF4) is central to the
transcriptional network of activated B-cell-like dif-
fuse large B-cell lymphoma (ABC-DLBCL), an ag-
gressive lymphoma subgroup defined by gene ex-
pression profiling. Since cofactor association modi-
fies transcriptional regulatory input by IRF4, we as-
sessed genome occupancy by IRF4 and endogenous
cofactors in ABC-DLBCL cell lines. IRF4 partners
with SPIB, PU.1 and BATF genome-wide, but SPIB
provides the dominant IRF4 partner in this context.
Upon SPIB knockdown IRF4 occupancy is depleted
and neither PU.1 nor BATF acutely compensates. In-
tegration with ENCODE data from lymphoblastoid
cell line GM12878, demonstrates that IRF4 adopts
either SPIB- or BATF-centric genome-wide distribu-
tions in related states of post-germinal centre B-
cell transformation. In primary DLBCL high-SPIB
and low-BATF or the reciprocal low-SPIB and high-
BATF mRNA expression links to differential gene
expression profiles across nine data sets, identify-
ing distinct associations with SPIB occupancy, sig-
natures of B-cell differentiation stage and poten-
tial pathogenetic mechanisms. In a population-based
patient cohort, SPIBhigh/BATFlow-ABC-DLBCL is en-
riched for mutation of MYD88, and SPIBhigh/BATFlow-
ABC-DLBCL with MYD88-L265P mutation identifies a
small subgroup of patients among this otherwise ag-
gressive disease subgroup with distinct favourable
outcome. We conclude that differential expression
of IRF4 cofactors SPIB and BATF identifies biologi-
cally and clinically significant heterogeneity among
ABC-DLBCL.
INTRODUCTION
Classiication based on gene expression has linked clini-
cal response to molecular biology in diffuse large B-cell
lymphoma (DLBCL), an aggressive and common form
of human lymphoma. The cell of origin classiication has
become a prevailing paradigm, and divides DLBCL into
groups based on their relationship to normal B-cell coun-
terparts: the germinal centre B-cell (GCB) and the acti-
vated B-cell type (ABC) (1). ABC-DLBCL has a worse
prognosis on currently standard immunochemotherapy reg-
imen R-CHOP (rituximab, cyclophosphamide, hydroxy-
daunorubicin, Oncovin, prednisolone) and is related to the
continuum of activated cell states that lie between B-cells
and plasma cells. This continuum is linked to a reorganiz-
ing transcriptional network driven by changes in expression
of core transcriptional regulators. We reasoned that varia-
tion in expression of these transcriptional regulators might
equally contribute to heterogeneity within ABC-DLBCL.
Interferon regulatory factor 4 (IRF4) is a deining fea-
ture of ABC-DLBCL and in normal B-cells is essential for
the initiation of plasma cell differentiation (2–5). TheDNA-
binding domain of IRF4 is restricted via an autoinhibitory
interaction (6), and release depends primarily on binding
to transcription factor partners. Two principle cofactors
of IRF4 are the ETS-family proteins PU.1 and SPIB, at
ETS/IRF Composite Elements (EICE) (7–9). While highly
related, SPIB and PU.1 are only partially redundant and
are essential for mature B-cell survival (10–12). SPIB can
additionally act to prevent plasma cell differentiation by re-
pressing PRDM1/BLIMP1 (13). In ABC-DLBCL SPIB is
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of particular relevance as this gene can be subject to dereg-
ulation by ampliication or translocation leading to hetero-
geneity in SPIB expression (14,15). A recent study reported
on the role of SPIB in ABC-DLBCL using biotin-tagged
SPIB for ChIP-seq assays, and concluded that SPIB/IRF4
heterodimers were central to ABC-DLBCL pathogenesis
potentially regulating B-cell receptor signalling pathways
and interferon- (IFN) secretion downstream ofMYD88
mutations (16). However, the contribution of endogenous
partners to regulatory element usage by IRF4 was not di-
rectly assessed.
BATF, an AP1-family protein (17), was recently de-
scribed as a principle IRF4 partner at AP1/IRF Compos-
ite Elements (AICEs) in T-cells and dendritic cells (18–21).
This partnership was also observed in cytokine stimulated
B-cells (19,20). BATF plays an essential role in both T- and
B-cells during humoral immune responses, with a require-
ment in the germinal centre and the regulation of class-
switch recombination via AICDA (22,23). However, in the
context of B-cell malignancy BATF is consistently associ-
ated with ABC-DLBCL, representative of a post-germinal
centre state, rather than GCB-DLBCL (24); BATF thus
provides a potential alternate partner for IRF4 in this con-
text.
Here, we have addressed the relationship between IRF4
and its endogenous partners in ABC-DLBCL. Our results
demonstrate that SPIB does provide the functionally dom-
inant IRF4 partner in ABC-DLBCL with SPIB deregula-
tion, however, in this context BATF provides an alternative
IRF4 partner genome-wide. We ind that in primary ABC-
DLBCL, variation in the expression of SPIB and BATF is
associated with clinical and biological heterogeneity. Strong
expression of SPIB relative to BATF is linked with bet-
ter overall survival, MYD88 mutations and expression of
genes associated with SPIB occupancy and B-cell rather
than plasmablast or plasma cell state.
MATERIALS AND METHODS
Antibodies and primers
Antibodies used were: IRF4 antibody (sc-28696X), PU.1
antibody (sc-352X), BATF antibody (sc-100974X, Santa
Cruz), BLIMP1 polyconal antibody as described (25),
monoclonal anti--ACTIN (clone AC-15, Sigma), rabbit
anti-mouse immunoglobulin G (IgG; Jackson ImmunoRe-
search), control rabbit IgG (Upstate Biotechnology), con-
trol mouse IgG (Sigma), anti-MYC clone 9E10.
Vectors and antibody generation
Coding sequence for human SPIB a.a.1–51 was cloned into
pGEX6P1 between EcoRI and BglII and sequence veri-
ied, for primers see Supplementary Methods. GST-fusion
proteins were expressed according to manufacturer’s in-
structions (Amersham) and used to generate rabbit poly-
clonal antisera according to standard procedures (Harlan
Seralab).
Myc-epitope tagged coding sequence for human SPIB,
SPI1(PU.1) and IRF4 were cloned into pIRES2EGFP
(Clontech) between EcoRI and BglII for SPIB, EcoRI and
BamHI for SPI1/PU.1 and IRF4, and sequence veriied.
Cell lines, culture, transfection and knockdown
H929, HeLa and COS cells were cultured in RPMI1640
media and OCI-LY3, OCI-LY10 (kind gift of Prof. R.E.
Davis) in Iscove’s Modiied Dulbecco’s Medium (IMDM)
with GlutaMAXTM (Life TechnologiesTM), each contain-
ing 10% heat inactivated fetal calf serum. COS and HeLa
cells were transfected with GeneJuice (Novagen) according
to the manufacturer’s instructions.
Western blot, ChIP and ElectrophoreticMobility Shift Assay
Western blots were performed according to standard pro-
cedures. ChIP and electrophoretic mobility shift assay
(EMSA) were performed as described (26). For BATF the
ChIP method was adapted such that protein A Sepharose
(Thermo Scientiic) was irst saturated with rabbit anti-
mouse secondary antibody, and then incubated with anti-
BATF or control mouse IgG. Pre-bound beads were used
to immunoprecipiate chromatin fractions. Nuclear extracts
for EMSA were prepared from transfected COS cells, and
OCI-LY3 and -LY10 cell lines. For EMSA probe sequences
and ChIP PCR primer sequences see SupplementaryMeth-
ods.
Library preparation and sequencing
Library preparation for input chromatin, IRF4, SPIB and
PU.1 was performed using the Illumina ChIP-seq Sample
Prep Kit (Illumina R©) according to manufacturer’s instruc-
tions, and run on a GAIIx Genome Analyser (Illumina R©,
Little Chesterford, UK). BATF samples, and libraries
generated for control siRNA and SPIB siRNA treated
chromatin were prepared using the MicroPlex Library
PreparationTM kit (Diagenode) for ChIP, size selected us-
ing AMPure XP beads (Beckman Coulter) and run on an
Illumina Hiseq 2500.
siRNA knockdown, RNA extraction and gene expression
analysis
OCI-LY3 and OCI-LY10 cells were transfected
with SPIB siRNA (s13354; 4392420––Ambion Life
TechnologiesTM) or control non-targeting siRNA, (27)
using Amaxa R© Nucleofector R© system and Amaxa R© Cell
line Nucleofector R©Kit V (Lonza), setting D.023, according
to manufacturer’s instructions. RNA was extracted with
TRIzol R© and ampliied using Illumina R© TotalPrepTM-96
RNA Ampliication Kit (Life TechnologiesTM). Resulting
cRNAs were then hybridized to BeadChips using the
HumanHT-12 v4 Expression BeadChip Kit according to
manufacturer’s instructions, and the BeadChips scanned
with the Illumina BeadArray Reader (Illumina R©). Analysis
was performed as previously described (28).
MYD88 mutation screening
Primary DLBCL samples related to GSE32918 were re-
trieved from the Haematological Malignancy Diagnostic
Service of Leeds Teaching Hospital NHS Trust. DNA from
representative sections was extracted using standard pro-
teinase K digestion and the QIAamp DNAMicro Kit (QI-
AGEN,Crawley,UK).MYD88 genemutationwas screened
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by PCR and Sanger sequencing. The primer sequences and
PCR conditions are detailed in Supplementary Methods.
PCR products were sequenced using the BigDye Termina-
tor v3.1 (Applied Biosystems, Foster City, CA, USA). Se-
quence changes were conirmed by at least two indepen-
dent PCR and sequencing experiments. The somatic muta-
tionwas ascertained by excluding germline changes through
database search and analysis of DNA from microdissected
normal cells.
Data sets and analysis
A set of 10 DLBCL data sets were used as previ-
ously described (24), including data sets derived from
the Gene Expression Omnibus: GSE32918, GSE10846,
GSE12195, GSE19246, GSE22470, GSE22895, GSE31312,
GSE34171, GSE4475, (29–37) as well as the data of
Monti et al. (10), and Wright et al. (http://llmpp.nih.gov/
DLBCLpredictor/) (38). The data set, GSE10846, was split
into treatment groups (CHOP/R-CHOP) yielding two data
sets that were then analysed independently (referred to
as GSE10846 CHOP and GSE10846 R-CHOP). Data set
GSE41208 covering progressive changes in gene expression
during plasma cell differentiation was previously described
(28). Data generated for this manuscript are available via
GSE50015 and GSE56857.
ChIP-seq data analysis and motif detection
For more detail see Supplementary Methods. Trimmed
reads were aligned with Bowtie2 (39), and analysed for
peaks using GEM (40). Peak overlaps were determined us-
ing a clustering approach such that any peak centre <250
bp from an index peak centre were considered part of an
overlapping cluster.De novomotif detection was performed
with HOMER (41). Displayed motifs are provided as ma-
trices in Supplementary Table S2. The Broad IGV tool was
used to display ChIP-seq data (42,43).
RESULTS
SPIB, PU.1 and IRF4 cis-regulatory occupancy in ABC-
DLBCL cell lines
Assessment of endogenous SPIB is essential in order to
understand how distinct cooperating factors contribute
to IRF4 regulatory element usage in ABC-DLBCL. We
therefore raised a polyclonal antibody against the variable
amino-terminus of the protein, which did not cross-react
with PU.1 or SPIC, and was validated in conventional ChIP
assays (Supplementary Figure S1A–C). We then performed
ChIP-seq for SPIB, PU.1 and IRF4 from the ABC-DLBCL
cell lines OCI-LY3 and OCI-LY10. We identiied 6379 and
13184 IRF4 sites, 2937 and 8904 PU.1 sites and 21055 and
14234 SPIB sites in OCI-LY3 and LY10, respectively (Sup-
plementary Table S1).
Occupancy of SPIB was conirmed at known targets
including BCL2A1, P2RY10, FCRL5, CD36, CD37 and
CD40 (Figure 1A and Supplementary Figure S2 and Table
S1) (16,44–46). SPIB occupancywas identiied at promoters
of genes previously deined as PU.1 targets, such asMS4A1
(CD20) (47), a critical element of the B-cell phenotype and
target of therapeutic monoclonal antibody rituximab, and
at promoters of several members of dispersed gene fami-
lies, such as TLR4, TLR7 and TLR9. SPIB binding was
also identiied across clustered gene families, such as SP100,
SP110 and SP140, and the FCRL1–5 cluster. Important
regulatory interactions for SPIB have been previously de-
ined, irst, in a positive feedback loop with the transcrip-
tional factor TCF4 (E2–2) during plasmacytoid dendritic
cell ontogeny (48,49), and, second, in a negative feedback
loop with PRDM1 (BLIMP1) during plasma cell differen-
tiation (13). Consistent with these regulatory interactions
binding of SPIB to the previously identiied PU.1/ETS-site
within the PRDM1 promoter (50), and binding to several
elements within the TCF4 gene was identiied (Supplemen-
tary Figure S2). Thus, the overall pattern of occupancy de-
tected for SPIB conirms known regulatory interactions,
and provides to our knowledge the irst genome-wide view
of SPIB occupancy for the endogenous protein.
The cistromes of all three assessed transcription factors
overlapped extensively between the two cell lines. Differ-
ences primarily derived from absolute numbers of binding
events in each cell type, thus for IRF4 we observed 95%
overlap of the LY3 cistrome among that of LY10, for PU.1
97% overlap of the LY3 cistrome among that of LY10 and
for SPIB 91% overlap of the LY10 cistrome among that
of LY3. As expected the cistromes of these factors were
also highly interrelated within each cell line (Figure 1B).
IRF4 occupancy occurred predominantly in the context of
one or other ETS-partner, encompassing 87% of the IRF4
cistrome in OCI-LY3 and 61% in OCI-LY10. More than
95% of these sites were bound in the presence of SPIB in
either cell line. Among sites occupied by ETS-factors with-
out IRF4, PU.1 alone made a minor contribution. In con-
trast, occupancy by SPIB in the absence of PU.1 was a com-
mon feature (SPIB Only 90% in LY3 and 50% in LY10;
factor names separated by underscores are used to denote
co-occupancy patterns in the remainder of the manuscript,
e.g. IRF4 and SPIB co-occupancy = IRF4 SPIB). At co-
occupied sites the peak centres showed a high degree of
overlap and for the majority of IRF4 occupied sites the
nearest peak centre for either SPIB or PU.1waswithin 50 bp
(Figure 1C). IRF4 occupancy in the absence of ETS-factors
showed the largest bias towards promoters in both cell lines
(34%), while other factor combinations showed lesser pro-
portions of promoter occupancy (12.5–23%).
For comparison we additionally assessed the H929
myeloma cell line, which expresses high levels of PU.1 rela-
tive to SPIB (Supplementary Figure S1C). ChIP-seq from
this cell line provides both an assessment of IRF4 occu-
pancy in a distinct transcription factor context, and an ad-
ditional control for the speciicity of the SPIB antibody
since the strong expression of PU.1 relative to SPIB would
be expected to result in a reversal of the cistrome sizes in
comparison to the two DLBCL cell lines. In the H929 cell
line we identiied 21946 PU.1, and 19755 IRF4 sites (Sup-
plementary Figure S3A and B). In contrast, only 1193 SPIB
sites were recovered which is consistent with the low level
of protein expression. Of the IRF4 cistrome in H929 cells,
63.5% was occupied by IRF4 in the absence of PU.1 or
SPIB, while 32.7% was occupied by IRF4 and PU.1. This
represented a signiicant shift in favour of IRF4 occupancy
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Figure 1. IRF4, SPIB and PU.1 distribution in ABC-DLBCL. (A) Representative examples of occupancy patterns for IRF4, PU.1 and SPIB in OCI-
LY3 and OCI-LY10 cells are shown, normalized read-counts/million are indicated to the left of each track. (B) Venn diagrams showing the overlap of
transcription factor cistromes for the indicated cell lines. (C) Density plots of the distribution of peak centres for SPIB (blue) and PU.1 (orange) relative
to IRF4 peak centres. The x-axis shows 500 bp up- and down-stream of IRF4 peak centres at 0.
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in the absence of an ETS-factor partner in H929 relative to
OCI-LY3 and LY10 (p-value = 2.2E–16 chi-squared test).
SPIB alone or in conjunction with PU.1 made only a minor
contribution to IRF4 occupancy in H929 myeloma cells.
Occupancy conirms motif identity for SPIB and PU.1, and
SPIB as predominant IRF4 partner at EICEs
PU.1 and SPIB have at most subtle differences in preferred
binding motif when assayed in vitro (8,51). Consistent with
this de novo motifs identiied in regions occupied by SPIB
alone or in combination with PU.1, matched the previously
deined consensus (Figure 2A and Supplementary Table S2)
(52). Equally, EICEs were recovered from sites occupied
by IRF4 and SPIB or PU.1 (Figure 2B) and at sites occu-
pied by IRF4 and PU.1 in the H929 myeloma (Supplemen-
tary Figure S3C). The detection by de novomotif discovery
of highly enriched motifs matching the in vitro determined
consensus for SPIB, and the canonical EICE at co-occupied
sites, provides further validation of the observed occupancy
patterns. At IRF4 SPIB PU.1 occupied sites a modestly in-
creased frequency of additional EICE and ETS motifs (not
overlapping with an adjacent EICE) was evident within 100
bp of the peak centre suggesting that some of these regions
have the potential for combined occupancy by all three fac-
tors (Supplementary Figure S4). We conclude that in these
ABC-DLBCL cell lines SPIB is the principle IRF4 partner
at regulatory regions encompassing EICEs.
SPIB regulates immune response genes
We next considered the relationship between local occu-
pancy by SPIB, PU.1 and IRF4 (deined as a peak less than
5 kb upstreamorwithin a gene body) and gene expression in
each cell line (Figure 3A). The bulk of genes associated with
local factor occupancy had low median expression values,
but the distributions were as expected shifted towards pos-
itive gene expression in each cell line. Overall IRF4 associ-
ated genes showed the greatest shift towards higher median
gene expression.
To further assess the relationship between SPIB occu-
pancy and gene regulation we performed siRNA knock-
down in OCI-LY3 and LY10 and assessed gene expression
at 48 h (Figure 3B), SPIB knockdown was not as well sus-
tained in OCI-LY10 and we therefore restricted analysis
to OCI-LY3. Three hundred and six gene probes showed
signiicant differences in expression on SPIB knockdown
(False Discovery Rate (FDR) adjusted p-value < 0.05),
corresponding to 283 genes (Supplementary Table S3).
Of genes changing expression following SPIB knockdown
71/133 downregulated (p-value= 1.43E-10) and 68/150 up-
regulated (p-value = 1.5E-06) genes were linked to SPIB
occupancy. Imposing a threshold of ≥1.5-fold change in
expression restricted this to 88 genes changing expression,
among which 25/46 downregulated (p-value = 4.06E-05)
and 18/42 upregulated (p-value = 1.18E-02) genes were
linked with local SPIB occupancy. This set of acutely re-
sponsive target genes, positively controlled by SPIB (Figure
3B), included the common elements of the ABC-DLBCL
proile CCND2 and NFKBIZ (1,14,24), as well as estab-
lished (SELL (Selectin-L/CD62L), CD40) and more re-
cently deined (FCRL2) regulators of B-cell immune re-
sponses (53).
BATF is an IRF4 co-factor in ABC-DLBCL cell lines
While genomic occupancy in the presence of SPIB repre-
sented the predominant mode in both OCI-LY3 and LY10
cells, sites occupied by IRF4 in the absence of SPIB and
PU.1 were of particular interest as these were likely to
include regions bound by IRF4 in the context of addi-
tional cofactors, such as BATF. This component of the
IRF4 cistrome included 839 peaks (13%) in OCI-LY3, but
a greater proportion in OCI-LY10, 5164 peaks (39%) (Fig-
ure 1B). Notably, de novo motif detection either from the
complete IRF4 cistrome from both ABC-DLBCL cell lines
or the IRF4 Only peak subsets identiied motifs matching
AICEs (Figure 4A and Supplementary Figure S5A). These
included both AICE-1 variants which place the AP1 com-
ponent of the motif 5′ of the ‘GAAA’ sequence bound by
IRFs with a 4-base spacing, and the AICE-2 variant in
which the orientation is inverted and the core IRF site is
immediately 5′ of the AP1 site.
We recently used a comparative analysis of gene expres-
sion across 10 DLBCL data sets to establish the genes most
consistently associated with ABC- and GCB-DLBCL (24).
BATFwas among the 24 genes that were associatedwith the
ABC-class in all data sets. We therefore performed EMSA
to assess the potential for BATF to form DNA-binding
complexes with IRF4 in the OCI-LY3 and LY10 cell lines.
Probes encompassing AICEs associated with SETBP1 and
FOXO3 genes both generated a dominant complex which
was super-shifted by IRF4 or BATF antibodies (Figure 4B).
As expected, mutation of the AP1 element of the consen-
sus eliminated the formation of this cocomplex. A greater
residual complex was observed on IRF4 antibody super-
shift, particularly in OCI-LY3 cells, and expression of IRF8
may provide an explanation for this observation as this fac-
tor can also form complexes with BATF at AICEs (20,21).
To assess the contribution of BATF to IRF4 binding
more generally we performed ChIP-seq for BATF from
both ABC-DLBCL cell lines (Figure 5A). This identiied
a total of 4735 and 10367 BATF peaks in OCI-LY3 and
LY10, respectively (Supplementary Table S4). These over-
lapped with IRF4 peaks both in the absence and in the pres-
ence of SPIB and PU.1 (Figure 5B), while a lesser fraction of
the BATF cistrome overlapped with SPIB or PU.1 in the ab-
sence of IRF4. Among peak regions occupied by BATF in
both cell lines classical AP1 motifs and AICEs were identi-
ied as enriched in de novo motif discovery (Figure 5C). We
manually validated a selection of 11 peak regions charac-
terized by different occupancy patterns for IRF4, SPIB and
BATF using ChIP-qPCR. These results veriied the detec-
tion of different occupancy patterns (Figure 6).
The position of IRF4 and BATF peak summits at co-
occupied sites showed similar distributions (Supplementary
Figure S5B). To evaluate motif usage at peak regions oc-
cupied by IRF4 with SPIB, PU.1 and BATF (IRF4 SPIB-
PU.1 BATF), or BATF alone (IRF4 BATF) we considered
the 200 most signiicant peak regions. IRF4 BATF occu-
pied regions were characterized by the expected AP1 and
AICE motifs and rarely contained matches to either EICEs
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Figure 2. De novomotif discovery at SPIB and PU.1 occupied regions. Sequence motifs discovered by de novomotif detection with HOMER are shown, at
regions occupied by (A) SPIB and/or PU.1 in the absence of IRF4, (B) SPIB and/or PU.1 in the presence of IRF4. Motifs are broken down by indicated
co-occupancy pattern. Shown are top ranked motifs with enrichment and percentage of peak regions with motif match. The ETS, PU.1/SPIB and EICE
consensus sequences are indicated for reference.
or ETS motifs. In contrast, IRF4 SPIB-PU.1 BATF occu-
pied regions contained matches to EICE, ETS, AP1 and
AICE motifs but few individual peak regions contained
matches to all four motifs (Supplementary Figure S5C).
Overall within this subset of multiply co-occupied peaks a
higher frequency of EICEs was observed relative to AICEs
indicating that SPIB is likely to provide the most common
direct IRF4 cofactor at these multiply co-occupied sites in
OCI-LY3 and LY10 cells.
Distinct IRF4 occupancy patterns relate to cofactor position-
ing in Epstein–Barr virus (EBV) LCLs and ABC-DLBCL
cell lines
Signalling via the LMP1 and LMP2A proteins plays a criti-
cal role in EBV lymphoblastoid transformation (54). These
viral proteins provide mimics of constitutive CD40 and B-
cell receptor signalling, corresponding to two critical path-
ways of oncogene activation in ABC-DLBCL (2). Lym-
phoblastoid cell lines, and in particular the ENCODE data
derived fromGM12878 LCLs (55), thus provide the oppor-
tunity for relevant comparison to ABC-DLBCL. We there-
fore assessed the IRF4, BATF and SPIB cistrome in OCI-
LY3 and LY10 cells, selecting the dominant ETS factor for
balanced data set number, against the IRF4, BATF and
PU.1 cistromes in ENCODE GM12878 data (55). The dis-
tributions of SPIB binding in the LY3 and LY10 cell lines
correlatedmost signiicantlywith that of PU.1 inGM12878,
while IRF4 binding in LY3 and LY10 cell lines correlated
most highly with that of SPIB, and weakly with the distri-
bution of PU.1 in GM12878 (Figure 7A). In contrast, the
IRF4 distribution in GM12878 correlated with BATF and
to a lesser extent with PU.1 in the matching cell line (56).
Thus, the overall positioning of IRF4 in two related con-
texts of post-germinal centre B-cell transformation shows
distinct linkage to either SPIB/PU.1 or BATF centred dis-
tributions.
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Figure 3. Gene expression associated with SPIB occupancy. (A) Gene expression values for OCI-LY3 (left panel) and LY10 (right panel) are shown as
density plots, with the median and interquartile ranges (25th–75th) shown as a central line for all genes (Total) or genes associated with local factor
occupancy (peak±2kb of TSS) as shown on the y-axis, with log2 expression values on the x-axis. (B) Summary of SPIB knockdown results, representative
western blot of SPIB knockdown in OCI-LY3 cells is shown on the left. The intersection of genes showing signiicant downregulation (adjusted p-value
<0.05, >1.5-fold change) following 48 h SPIB knockdown with those also showing local SPIB occupancy (5 kb upstream/intragenic) is illustrated in the
diagram on the right.
SPIB is the functionally dominant IRF4 co-factor in the
OCI-LY3 ABC-DLBCL cell line
The overall frequency of IRF4 and SPIB co-occupancy, and
the genome-wide correlation analysis supported a domi-
nant role for SPIB in determining IRF4 occupancy in the
ABC-DLBCL cell lines. However, the extent to which SPIB
provided an essential determinant of IRF4 DNA-binding
in this context was uncertain; to address this question, we
knocked-down SPIB expression in OCI-LY3 cells, to a de-
gree suficient to impact on both SPIB and IRF4 binding at
a selected positive control site (Figure 7B), and performed
ChIP-seq for SPIB, PU.1 and IRF4. Overall we observed
a highly signiicant loss of SPIB but not PU.1 occupancy
genome-wide, further validating the speciicity of our SPIB
ChIP-seq data (Figure 7B and C). Although a subset of reg-
ulatory elements did show a reciprocal increase in PU.1 oc-
cupancy on SPIB depletion, such as a regulatory element
near CD28 shown in Figure 7D, generally PU.1 did not
compensate for SPIB depletion by increased binding (Fig-
ure 7C). In contrast, depletion of SPIB was accompanied
by a genome-wide loss of IRF4 occupancy. Even among
those sites bound by IRF4 in the absence of either ETS-
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Figure 4. Association of BATF and IRF4 in ABC-DLBCL. (A) AICE motif variants identiied by de novo motif detection among the complete IRF4
cistrome in OCI-LY3 and OCI-LY10 are shown as logos, along with the signiicance of enrichment and percent of peak regions with a motif match. (B)
EMSA was performed with nuclear extracts of OCI-LY3 and LY10 cells using probes corresponding to wild type (left pairs of images) and mutated AICE
motifs (right pairs of images) at IRF4 occupied sites in SETBP1 (upper panels) and FOXO3 (lower panels) genes. Binding partners were conirmed using
indicated speciic antibodies. Arrows identify primary BATF/IRF complex, and supershifted bands labelled ‘S’. Sequence of oligos used in EMSA with
mutated bases where relevant are indicated below each panel.
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Figure 5. BATF occupancy in ABC-DLBCL. (A) Illustrates representative examples of BATF, IRF4, PU.1 and SPIB occupancy patterns in OCI-LY3 and
OCI-LY10. (B) Venn diagram illustrating the extent of overlap between BATF, IRF4 and merged PU.1/SPIB cistromes in OCI-LY3 (left) and OCI-LY10
(right). (C) Representative motifs recovered from de novo motif detection for each cell line (OCI-LY3 left; OCI-LY10 right) illustrating the most common
recovered motif of AP1 type, and AICE motif variants identiied amongst the total BATF cistrome. Consensus sequences for AP1, AICE-1 and AICE-2
motifs are illustrated for reference.
factor partner an overall loss of IRF4 occupancy was ob-
served, which contrasted with the absence of any impact on
IRF4 mRNA expression on SPIB knockdown (Figure 7C
IRF4 Only and Supplementary Table S3). However, using
the set of regulatory elements bound by IRF4 in the absence
of either PU.1 or SPIB for comparison (IRF4 Only), the
loss of IRF4 binding on SPIB knockdown was signiicantly
greater at sites co-occupied by IRF4 in the presence of
SPIB irrespective of PU.1 co-occupancy (IRF4 SPIB Only,
p-value= 6.85E-28; IRF4 SPIB PU.1, p-value= 5.47E-26).
Furthermore, although genome-wide occupancy by IRF4
was responsive to loss of SPIB, a small fraction (∼8%)
of all IRF4 occupied sites was unaffected by SPIB deple-
tion (fold-change <1.4). This stable subset of IRF4 occu-
pied sites was signiicantly enriched for regulatory elements
bound by IRF4 in the absence of SPIB (43%, p-value =
1.23E-29). Thus, in the OCI-LY3 ABC-DLBCL cell line,
PU.1 fails to compensate acutely for SPIB depletion and a
general-shift towards an alternate pattern of BATF-centred
IRF4 occupancy is not observed. However, while IRF4 oc-
cupancy is globally responsive to SPIB knockdown, those
sites occupied by IRF4 in the absence of SPIB are as ex-
pected most resilient. We conclude that in this context SPIB
provides the functionally dominant determinant of IRF4
genomic occupancy, and neither PU.1 nor BATF acutely
compensate to maintain IRF4 occupancy or drive redistri-
bution of IRF4 to a different occupancy pattern.
 at U
niversity of Leeds on M
arch 17, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
7600 Nucleic Acids Research, 2014, Vol. 42, No. 12
BATF_IRF4 SPIB_IRF4 SPIB_Only
0
10
20
30
40
50
60
70
80
ch
r1
0
12
41
34
87
2
ch
r1
8
12
30
96
14
ch
r1
1
47
20
87
0
ch
r1
8
42
28
96
64
FA
M
12
9C
CD
23
TL
R4
ch
r5
14
13
03
10
8
ch
r1
11
00
90
87
0
ch
r1
15
60
25
54
74
IRF4
0
20
40
60
80
100
120
140
160
180
200
ch
r1
0
12
41
34
87
2
ch
r1
8
12
30
96
14
ch
r1
1
47
20
87
0
ch
r1
8
42
28
96
64
FA
M
12
9C
CD
23
TL
R4
ch
r5
14
13
03
10
8
ch
r1
11
00
90
87
0
ch
r1
15
60
25
54
74
SPIB
0
2
4
6
8
10
12
14
16
ch
r1
0
12
41
34
87
2
ch
r1
8
12
30
96
14
ch
r1
1
47
20
87
0
ch
r1
8
42
28
96
64
FA
M
12
9C
CD
23
TL
R4
ch
r5
14
13
03
10
8
ch
r1
11
00
90
87
0
ch
r1
15
60
25
54
74
BATF
F
o
ld
 e
n
ri
ch
m
e
n
t 
o
v
e
r 
co
n
tr
o
l 
Ig
G
F
o
ld
 e
n
ri
ch
m
e
n
t 
o
v
e
r 
co
n
tr
o
l 
Ig
G
F
o
ld
 e
n
ri
ch
m
e
n
t 
o
v
e
r 
co
n
tr
o
l 
Ig
G
Figure 6. Differential occupancy patterns are conirmed by manual validation. Shown are representative results for BATF, SPIB and IRF4 ChIP using
qPCR at selected targets representative of IRF4 BATF, IRF4 SPIB and SPIB Only occupancy patterns as indicated at the bottom of the igure. Results are
shown as fold enrichment relative to control IgG on the y-axis, promoter regions are indicated using oficial gene symbol, while other regulatory elements
are indicated by genomic position (hg19) of the forward primer. Results are representative of two independent experiments from different chromatin batches
derived from OCI-LY10 cells.
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Figure 7. SPIB can act as a functionally dominant IRF4 partner in ABC-DLBCL. (A) IRF4 shows SPIB or BATF predominant genome-wide positioning
in different contexts of post-germinal centre transformation. The genome-wide distribution of BATF, IRF4 and SPIB in OCI-LY3 and LY10 was compared
to the distribution of BATF, IRF4 and PU.1 in ENCODE GM12878 data by Pearson’s correlation. The pairwise correlations of occupancy determined
at 100 bp resolution, are illustrated as a hierarchically clustered heat-map (blue = -0.2, white = 0.2 and red = 0.9 Pearson’s correlation coeficient). (B)
SPIB knockdown at 48 h was conirmed by western blot, and the degree of knockdown was conirmed by densitometry relative to ACTIN loading control,
for cells used in ChIP-seq analysis. The effect of knockdown, in matching chromatin, was evaluated by qPCR at a positive control regulatory element in
the FAM129C promoter for IRF4, SPIB and PU.1 ChIP samples. Results are shown as fold enrichment over control IgG. (C) Illustrates the genome-wide
analysis of the impact of SPIB knockdown shown in (B) on the occupancy of IRF4, PU.1 and SPIB indicated in coloured bars beneath graph, at regulatory
elements divided according to the occupancy context shown as x-axis labels. The box and whisker plots display the log2 fold change in factor occupancy
between control siRNA and SPIB siRNA treated OCI-LY3 cells, across all merged regulatory elements of the indicated occupancy type. Signiicances
are indicated in the text, only the comparison of PU.1 total versus IRF4 PU.1 SPIB were not signiicantly different, all other comparison are signiicant
at p-value ≤ 7.7E-04. (D) Illustrates examples of IRF4, PU.1 and SPIB occupancy in OCI-LY3 cells in control and SPIB siRNA treated OCI-LY3 cells.
Changes in peak height can be compared for each transcription factor by setting the visualized reads/million to the same maximum value observed for
each transcription factor at the indicated region.
 at U
niversity of Leeds on M
arch 17, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
7602 Nucleic Acids Research, 2014, Vol. 42, No. 12
SPIB occupancy is linked to genes overexpressed in primary
ABC-DLBCL with high SPIB and low BATF expression
The intensity of SPIB expression has been linked to genomic
ampliication or translocation of chr19 in ABC-DLBCL
(14), and SPIB shows a less consistent differential expres-
sion betweenGCB- andABC-DLBCL than BATF (24).We
reasoned, therefore, that the relative expression of BATF
and SPIB might contribute to heterogeneity of tumour bi-
ology among ABC-DLBCL.
Although the classiication of DLBCL into cell of origin
classes has provided a central framework for understand-
ing this disease, a number of different algorithms have been
used to implement the classiication in different studies. We
recently described a detailed evaluation of classiier algo-
rithms across a range of available DLBCL gene expression
data sets (24).We established a robust platform independent
classiier tool, the DLBCL Automatic Classiier (DAC),
which allows consistent classiication of multiple data sets
and is effective on data generated both from fresh frozen
and formalin-ixed parafin embedded samples. With this
tool we previously performed a meta-analysis of gene ex-
pression across 10 uniformly classiiedDLBCLgene expres-
sion data sets (24). To address whether the relative expres-
sion of BATF and SPIB might contribute to disease hetero-
geneity, we irst examined the pairwise correlation of these
transcription factors in ABC-DLBCL using the cases con-
tained in the 10 publically available data sets and the classi-
ications of these cases that we have previously established
using DAC (24). In this analysis, one data set (GSE19246)
emerged as a consistent outlier and was therefore excluded
from further assessment. Each transcription factor pair-
ing showed evidence of a modest positive correlation; how-
ever, overall there was a greater positive correlation of IRF4
and BATF (average Spearmann’s correlation= 0.53± 0.08)
than SPIB and BATF (average Spearmann’s correlation =
0.40 ± 0.09) or IRF4 and SPIB (average Spearmann’s cor-
relation = 0.42 ± 0.09) (Supplementary Figure S6).
We reasoned that since SPIB and BATF provide distinct
regulatory information, the observed variability in BATF
and SPIB mRNA expression in ABC-DLBCL might be
associated with differences in disease biology. To address
this we separated the ABC-DLBCL cases into four groups,
by using a contingency table approach divided by high
and/or low expression of BATF and SPIBmRNA (top and
bottom 50% of expression as threshold). We then deter-
mined differential gene expression (p-value< 0.05) between
ABC-DLBCL cases characterized by the two extremes of
high-SPIB and low-BATF versus high-BATF and low-SPIB
mRNA expression in each data set. We subsequently re-
fer to these subgroups as SPIBhigh/BATFlow-ABC-DLBCL
and SPIBlow/BATFhigh-ABC-DLBCL. To identify genes
consistently associated with either of these two extremes we
used a threshold of differential expression in four or more
data sets, and refer to the resulting lists as ‘meta-proiles’.
In this pairwise comparison a total of 198 genes were iden-
tiied as overexpressed in SPIBhigh/BATFlow-ABC-DLBCL
and 237 genes in SPIBlow/BATFhigh-ABC-DLBCL (Sup-
plementary Table S5).
As an approximate assessment of the relationship be-
tween SPIB, BATF and IRF4 expression in OCI-LY3 and
LY10 cell lines and primary ABC-DLBCLs we superim-
posed the normalized expression values for these cell lines
onto the distributions derived for primary ABC-DLBCL
across all data sets. With the caveat that gene expression as-
sessments from primary tumour samples derive frommixed
cell types, this conirmed thatOCI-LY3 andLY10 fell within
the general distribution of expression values for BATF and
IRF4, and at the high end of the SPIB distribution (Fig-
ure 8A). We then assessed the overlap between local SPIB
and BATF occupancy in OCI-LY3 and LY10 cells and the
meta-proiles of SPIBhigh/BATFlow and SPIBlow/BATFhigh-
ABC-DLBCL (Figure 8B). Genes with occupancy by SPIB
or BATF, within the gene body or 5 kb upstream, were
signiicantly enriched among both SPIBhigh/BATFlow and
SPIBlow/BATFhigh-ABC-DLBCL meta-proiles. However,
SPIB occupancy showed a substantially more signiicant
enrichment in the SPIBhigh/BATFlow meta-proile (p-value
= 3.43E-23), than the SPIBlow/BATFhigh meta-proile (p-
value = 4.47E-11). In contrast, BATF occupancy showed
only a minor difference in enrichment between the two
meta-proiles (SPIBhigh/BATFlow meta-proile p-value =
2.62E-09 versus SPIBlow/BATFhigh meta-proile p-value
= 9.77E-08). This supports a direct regulatory contribu-
tion by SPIB to preferential gene expression in primary
SPIBhigh/BATFlow-ABC-DLBCL.
SPIBhigh/BATFlow and SPIBlow/BATFhigh-ABC-DLBCL
are reciprocally linked to distinct stages of B-cell differenti-
ation
The biology of ABC-DLBCL is related to cells trapped
in abortive plasma cell differentiation. We noted that dur-
ing in vitro B-cell differentiation to plasma cells, BATF
expression was induced in activated B-cells prior to the
loss of B-cell phenotype, while SPIB is modestly reduced
in activated B-cells and repressed upon transition to plas-
mablasts (Supplementary Figure S7). We, therefore, con-
sidered that the differences in gene expression linked to
the subgroups of ABC-DLBCL deined by relative SPIB
and BATF expression might also relate to different stages
of B-cell to plasma cell differentiation. To address this
we intersected the meta-proiles for SPIBhigh/BATFlow
and SPIBlow/BATFhigh-ABC-DLBCLwith gene expression
data, derived from an in vitro model we have recently de-
veloped, spanning the in vitro differentiation of resting hu-
man B-cells to long-lived plasma cells (28). Notably, both
meta-proiles were signiicantly enriched for genes show-
ing dynamic expression changes during B-cell to plasma
cell differentiation (54/193 SPIBhigh/BATFlow p-value =
2.14E-11, 62/235 SPIBlow/BATFhigh p-value = 1.15E-11).
Furthermore, the meta-proiles were also skewed relative
to the B-cell differentiation time course (Figure 8C and
D). SPIBhigh/BATFlow-ABC-DLBCL was positively asso-
ciated with genes with maximal expression in B-cells (Z-
score = +6.1, p-value = 0) and signiicantly depleted of
genes expressed at later stages of differentiation in partic-
ular the in vitro activated B-cell state (AB genes Z-score =
−3.7, p-value = 2.4E-06). In contrast, SPIBlow/BATFhigh
ABC-DLBCL showed a reciprocal pattern of association
with signiicant enrichment of in vitro activated B-cell
genes (Z-score = 2.97, p-value = 0.003) and signiicant
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Figure 8. SPIBhigh/BATFlow and SPIBlow/BATFhigh-ABC-DLBCL are differentially associated with transcription factor occupancy and stages of B-cell
differentiation. (A) The normalized expression values for SPIB, BATF and IRF4 mRNA in OCI-LY3 and LY10 cells are shown relative to expression of
these factors in primary ABC-DLBCL across 9 gene expression data sets. The scatter plots illustrate pairwise comparisons as indicated by arrow labels,
x- and y-axis represent normalized expression values as z-scores. The correlation is indicated as a line with 95% conidence interval as shading, and the
expression values for OCI-LY3 and OCI-LY10 are shown as red and blue spots, respectively. (B) The enrichment of genes (hypergeometric test) with local
SPIB and BATF occupancy (−5 Kb or intragenic) in OCI-LY3 and LY10 is shown, as indicated on the left of the bar graph, among the meta-proiles for
SPIBhigh/BATFlow (orange bars) and SPIBlow/BATFhigh-ABC-DLBCL (yellow bars). The bar graph illustrates the Log10p-value to the left and Z-score
to the right on the x-axis. (C) The enrichment or depletion of genes maximally expressed at different stages of in vitro human B-cell differentiation to
the plasma cell stage, among SPIBhigh/BATFlow (orange bars) and SPIBlow/BATFhigh-ABC-DLBCL (yellow bars) meta-proiles was determined using a
bootstrapping approach (1E7 randomizations). Shown are z-scores on the y-axis relating to categories following the order B-cell (BC), activated B-cell (AB),
plasmablast (PB) and plasma cell (PC) as indicated from left to right. The dotted line represents p-value of 0.05 (D) The SPIBhigh/BATFlow (orange bar) and
SPIBlow/BATFhigh-ABC-DLBCL (yellow bar) meta-proiles are shown as Wordles with the degree and consistency of differential expression represented
by font size, also indicated is the enrichment of meta-proile genes among genes showing dynamic expression during B-cell terminal differentiation in the
heat-map (blue to red colour scale representing low to high mRNA expression) to the right.
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depletion of genes expressed in resting B-cells (Z-score
= −3.33, p-value = 7.05E-05). However, there was no
signiicant difference, between the SPIBhigh/BATFlow and
SPIBlow/BATFhigh-ABC-DLBCL subgroups, in the expres-
sion of classiier genes used to establish the ABC versus
GCB-DLBCL classiication or the DAC-classiication con-
idence, which provides an overall assessment for each case
of the likelihood of belonging to one of the classes of the cell
of origin classiication (Supplementary Table S6). We con-
clude that these two subgroups show similar expression of
the principle classiier genes used to identify ABC-DLBCL
but differ in their relationship to stages of B-cell differen-
tiation: the SPIBhigh/BATFlow-ABC-DLBCL subgroup is
characterized by preferential retention of genes expressed in
resting B-cells, while SPIBlow/BATFhigh-ABC-DLBCL dis-
plays a more exaggerated similarity to in vitro activated B-
cells.
SPIBhigh/BATFlow and SPIBlow/BATFhigh ABC-DLBCL
are linked to distinct gene sets
In order to gain further insight into the potential re-
lationships of SPIBhigh/BATFlow and SPIBlow/BATFhigh-
ABC-DLBCL and previously deined molecular path-
ways, we performed an analysis of gene signature en-
richment using a hypergeometric test. The extensive com-
pendium of gene signatures tested were derived from Gen-
eSigDB, MSigDB, Staudt, Shipp and Du laboratories,
and were iltered for gene signatures of less than 1000
genes in size (13978 in total) (34,57–60). After correc-
tion for false discovery there remained an extensive list
of enriched signatures for both meta-proiles. At FDR
corrected p-value < 0.001, 109 and 281 gene signatures
overlapped signiicantly with the SPIBhigh/BATFlow and
the SPIBlow/BATFhigh meta-proiles, respectively (Supple-
mentary Table S7). The SPIBhigh/BATFlow meta-proile
showed most signiicant overlap with signatures of the
resting B-cell state (e.g. Pan B U133plus, FDR p-value
= 2.37E-15, Blood Module-1.3 B cells, FDR p-value =
1.72E-11), but also showed enrichment of signatures re-
lated to the activated B-cell lymphoma class (e.g. ABCgt-
GCB U133AB, FDR p-value = 1.24E-09) as well as sev-
eral signatures related to plasmacytoid dendritic cells (e.g.
Dendritic cell CD123pos blood, FDR p-value= 2.21E-10;
GSE29618 PDC VS MDC UP, FDR p-value= 4.13E-10).
In relation to SPIB itself, the SPIBhigh/BATFlow meta-
proile was notably enriched both for an external signa-
ture related to evolutionarily conserved PU.1/SPIB mo-
tifs in gene promoters (MSigDB C3 signature RGAG-
GAARY V$PU1 Q6, FDR p-value = 9.42E-06) and
importantly also for expression of genes in chr19q13
(MSigDB C1 signature chr19q13, FDR p-value = 8.38E-
05), the cytoband containing the SPIB gene, while no other
cytoband showed enrichment at FDR corrected p-value <
0.001 for either meta-proile. Interestingly, when consid-
ering genes 2Mb either side of the SPIB transcriptional
start site, enrichment was exclusively observed for genes
upstream/centromeric to SPIB (Supplementary Table S7).
Coexpression of genes associated with chr19 ampliication,
as described by Lenz et al. (14), in the SPIBhigh/BATFlow
meta-proile suggests that such ampliication is a contribut-
ing factor to the pathogenesis of this subgroup identiiable
from expression proiles.
In contrast, the SPIBlow/BATFhigh meta-proile
was most signiicantly enriched for genes asso-
ciated with STAT3 activation in ABC-DLBCL
(STAT3high ABC DLBCL subgroup, FDR p-value =
2.85E-17), while among other signaling pathway signatures
those linked to nuclear factor kappa-light-chain-enhancer
of activated B cells (NFB) in ABC-DLBCL were also
signiicantly enriched (e.g. NFKB UP BCR paper, FDR
p-value = 2.22E-08; BASSO CD40 SIGNALING UP,
FDR p-value = 6E-05) (Supplementary Table S7). This
is also consistent with the enrichment of genes at the
activated B-cell stage of in vitro differentiation (Figure 8D),
since this is driven by addition of IL21, a potent STAT3
activator, and CD40 ligation. However, it is worth noting
that the SPIBlow/BATFhigh meta-proile does not overlap
with all STAT3 related signatures to a similar degree. Genes
included in a recent expression-based signature of STAT3
activation, in DLBCL as a whole (61), showed no signif-
icant enrichment in the SPIBlow/BATFhigh meta-proile
(HUANG PY STAT3 Total, overlap 2/32, FDR p-value
= 0.2, or HUANG PY STAT3 11Sig, overlap 0/11 genes,
FDR p-value = 0.95). We conclude that separating the
ABC-DLBCL subset according to relative expression of
the two IRF4 cofactors SPIB and BATF identiies sub-
groups differentially linked to previously deined features
of DLBCL tumour biology.
High SPIB expression is linked to a group of ABC-DLBCL
with good clinical outcome
We noted that the SPIBhigh/BATFlow-ABC-DLBCL sub-
group in our U.K. population-based patient cohort
of DLBCL treated with R-CHOP chemotherapy (62),
(GSE32918), was characterized by a relatively good sur-
vival and included a subgroup of patients with survival be-
yond 5 years (Figure 9A). Since case numbers were limit-
ing we next asked whether a similar association between
survival and differential SPIB and BATF expression could
be observed in other data sets of cases treated with sim-
ilar immunochemotherapy. We irst examined this associ-
ation in the data set GSE10846, generated by the Lym-
phoma Leukemia Molecular Proiling Project (LLMPP),
which is the largest available data set derived from fresh
frozen, rather than formalin-ixed parafin embedded ma-
terial, and has provided a reference data set for the asso-
ciation between gene expression proiles and clinical out-
come in DLBCL in the era of immunochemotherapy (29).
In this data set SPIBhigh/BATFlow-ABC-DLBCL was simi-
larly characterized by a good outcome (Figure 9B).
Since the choice of algorithm used to implement the cell
of origin classiication does affect the classiication of a
subset of cases with marginal expression values for classi-
ier genes (24), we also addressed whether the association
of outcome with the differential SPIB/BATF expression
was affected by the use of our implementation of the cell
of origin classiier. However, this was not the case since a
similar good outcome was observed for SPIBhigh/BATFlow-
ABC-DLBCL cases when using the pre-assigned classes for
GSE10846 in the Gene Expression Omnibus (Supplemen-
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Figure 9. SPIB and BATF expression is linked to outcome and MYD88 mutation status in ABC-DLBCL. (A) Shows Kaplan–Meier analysis for overall
survival of SPIBhigh/BATFlow (blue line), compared to SPIBlow/BATFhigh-ABC-DLBCL (red line) cases in data set GSE32918. (B) Displays the Kaplan–
Meier analysis for overall survival of SPIBhigh/BATFlow (blue line), compared to SPIBlow/BATFhigh-ABC-DLBCL (red line) cases in data setGSE10846R-
CHOP component, using cases classiied as ABC-DLBCL with our implementation of the cell of origin classiication, DAC. (C) Illustrates the enrichment
of MYD88-L265P mutations among the four ABC-DLCBL subgroups deined by high/low SPIB and high/low BATF mRNA expression. The y-axis
represents the log2 of the p-value of enrichment. Signiicant enrichment is only observed in the SPIB
high/BATFlow subgroup indicated by a star. (D)
Illustrates Kaplain–Meier analysis of overall survival for ABC-DLBCL cases in data set GSE32918, divided according to MYD88 mutation status, wild
type (black line),MYD88-L265P mutation and SPIBhigh/BATFlow expression proile, or all otherMYD88-L265P mutated ABC-DLBCL cases (red line).
MYD88 mutations other than L265P, detected by Sanger sequencing, of which there were three cases were included in the ‘wild type’ category to relect a
clinical scenario of targetedMYD88-L265P mutation detection.
tary Figure S8). This was consistent with the fact that the
assignments of DLBCL to cell of origin classes differ for
only a minority of cases overall between our classiications
and those previously assigned to cases in GSE10846 (24).
In contrast to the concordant results observed be-
tween the LLMPP data, GSE10846 (29), and our U.K.
population-based data, GSE32918 (62), when we examined
a separate data set of R-CHOP treatedDLBCL cases gener-
ated by The International DLBCLRituximab-CHOP Con-
sortium Program (GSE31312) (37), we found no signii-
cant difference in survival between SPIBhigh/BATFlow and
SPIBlow/BATFhigh-ABC-DLBCL. Nonetheless, the con-
cordant results observed in GSE10846 and GSE32918 in-
dicate that high SPIB and low BATF expression can iden-
tify a subgroup of ABC-DLBCL cases with good outcome,
which in the context of our U.K. population-based cohort
includes a small subset of ABC-DLBCL cases treated with
R-CHOP displaying 5 year or greater survival.
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SPIBhigh/BATFlow-ABC-DLBCL is linked toMYD88muta-
tion status and the combination identiies a group with distinct
favourable outcome
MYD88 mutation is an oncogenic event strongly associ-
ated withABC-DLBCL andWaldenstrommacroglobuline-
mia, the recurrent L265P mutation of MYD88 accounts
for the majority of this association (63,64). MYD88 is a
principle signal transduction component downstream of
TLRs and IL1R. A functional linkage between SPIB ex-
pression and TLR/MYD88 pathway activation has been
identiied by Yang et al. in which SPIB represses autocrine
IFN secretion allowing ABC-DLBCL survival in the con-
text of MYD88 mutation (16). At the same time, while the
presence of a MYD88 mutation may promote receptor-
independent signalling (63), TLR activation also con-
tributes to signal transduction in the context of MYD88-
L265P inABC-DLBCL and in B-cells engineered to express
mutant MYD88 (65,66). The MYD88-L265P mutation is
present in both OCI-LY3 and LY10 cells (63), and we noted
that SPIB binding was present in the promoters of TLR4,
7 and 9 and in the vicinity of MYD88 itself in these cells.
We, therefore, asked whether an association between SPIB
expression and MYD88 mutation might also be observed
in primary ABC-DLBCL. We examined theMYD88muta-
tion status of ABC-DLBCL cases in our cohort (62), and
found a statistically signiicant association between cases
with high SPIB and low BATF expression and the pres-
ence of a MYD88 mutation in general (7/9 cases, p-value
= 0.015), or the commonMYD88-L265P mutation in par-
ticular (6/9 cases, p-value = 0.03) (Figure 9C and Supple-
mentary Table S8). In contrast, there was no signiicant as-
sociation between MYD88 mutation status and any of the
other combinations of SPIB and BATF expression, among
which MYD88 mutations were randomly distributed. No-
tably, among the six SPIBhigh/BATFlow-ABC-DLBCL pa-
tients with MYD88 mutations all but one survived for 5
years or more, the patient who died during follow-up was
an 85-year-old who survived for 2.5 years but had not re-
ceived treatment with curative intent. Thus, the identiica-
tion of SPIBhigh/BATFlow mRNA expression may provide
a tool to identify a subset of ABC-DLBCL patients with
MYD88-L265P mutation who have a good response to cur-
rent immunochemotherapy.
DISCUSSION
IRF4 is at the centre of both the transcriptional program of
B-cell terminal differentiation and of ABC-DLBCL. IRF4
engages in cooperative interactions with different transcrip-
tion factor partners at distinct DNA elements (5,67), pro-
viding the basis for varied transcriptional input across cell
states. Our indings suggest that the balance of IRF4 part-
ner expression between SPIB and BATF identiies distinct
subgroups of ABC-DLBCL linked to different stages of B-
cell differentiation, oncogenic pathway activation and clin-
ical outcome.
While several potential IRF4 transcription factor part-
ners have been described (5), recent genome-wide studies
have so far identiied three predominant modes of IRF4
DNA-binding: at EICEs (16), at AICEs (18–20) and at
repeats of the IRF ‘GAAA’ core consensus matching the
ISRE pattern (18,68). A shift in favour of IRF4 binding at
ISRE-like sequences has recently been identiied as a tran-
sition point during plasma cell differentiation (69). These
modes of DNA-binding by IRF4 are not mutually exclu-
sive. In theOCI-LY3 andLY10ABC-DLBCL cell lines, mo-
tif enrichment provided evidence for all three patterns of
occupancy with EICEs predominating over co-occupancy
with BATF at AICEs or occupancy at ISRE containing se-
quences. In the myeloma cell line H929, IRF4 occupancy
in the context of AICEs was not observed, which is most
likely to relect absent or low BATF expression. While PU.1
expression in H929 cells resulted in frequent occupancy of
IRF4 at EICEs, nonetheless IRF4 occupancy in the absence
of PU.1 at regulatory elements characterized by ISRE or
simple ‘GAAA’ core elements was most frequent. Of note,
PU.1 expression is not uniform across primarymyelomas or
myeloma cell lines, suggesting the potential for signiicant
variation in transcriptional input from IRF4 in plasma cell
malignancies, which will be important to explore in future.
Frequent IRF4 occupancy at regulatory elements con-
taining EICEs was recently described in the HBL1 ABC-
DLBCL cell line by Yang et al. (16). This study addition-
ally examined SPIB occupancy, and thus identiied a central
role for IRF4 SPIB heterodimers in several aspects of ABC-
DLBCLbiology.However, the use ofHBL1 cells engineered
to express biotin-tagged SPIB meant that the relative con-
tribution of endogenous SPIB or PU.1 to IRF4 occupancy
was not established. Here, we have addressed this issue and
our data put the role of IRF4 SPIB heterodimers in ABC-
DLBCL in a new context. In cell lines with strong SPIB
expression this association is both quantitatively and func-
tionally dominant, as shown by the fact that SPIB knock-
down in the OCI-LY3 cell line leads to extensive loss of
IRF4 DNA-binding, without compensation by PU.1 or re-
distribution of IRF4 to a more BATF-centred distribution.
However, our data also show that input from SPIB is mod-
iied by a signiicant contribution from BATF both in the
context of combined occupancy of regulatory elements by
BATF, IRF4 and SPIB and as an independent IRF4 cofac-
tor.
Comparison to ENCODE data demonstrates that the
pattern of IRF4 occupancy in ABC-DLBCLs differs sig-
niicantly from that in the EBV lymphoblastoid cell line
GM12878. In the latter cell line a dominant contribution
is made by BATF to IRF4 occupancy and BATF emerges
as more highly correlated with IRF4 than PU.1 genome-
wide (56). Thus, the GM12878 LCL provides a contrasting
instance in which BATF is the predominant IRF4 partner
in a transformed post-germinal centre B-cell. Interestingly,
EBV-derived transcription factors expressed in LCLs have
been recently shown to extensively cooccupy regulatory ele-
ments bound by BATF, IRF4 and PU.1 (70,71), and BATF
has been previously identiied as a direct target induced
by EBNA2 (72). It will therefore be important to estab-
lish whether a BATF-centred IRF4 distribution can occur
during B-cell activation or in primary SPIBlow/BATFhigh-
ABC-DLBCLs, or whether this pattern of occupancy ob-
served in GM12878 cells relects a regulatory state speciic
to EBV transformation. If so this would be predicted to
pertain as the predominant mode of IRF4 occupancy in
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EBV-driven B-cell malignancies, such as EBV-associated
DLBCL and EBV-associated classical Hodgkin lymphoma.
Together the data are consistent with a general model of
context-dependent IRF4 activity, and indicate that IRF4
expression in post-germinal centre B-cells malignancies can
be linked to several quite distinct transcriptional states.
It is inevitable that a disease category, such as ABC-
DLBCL, encompasses heterogeneity, but this is particu-
larly relevant where one of the principle classiier genes
used to establish the category encodes a transcription fac-
tor that can display the wide range of cis-regulatory oc-
cupancy observed for IRF4. The interest of analysing the
nature of this heterogeneity lies on the one hand in iden-
tifying signiicant differences in clinical outcome and on
the other in what such heterogeneity indicates in relation
to disease biology. The biological validity of subdividing
ABC-DLBCL based on SPIB and BATF expression is sup-
ported by the reciprocal association of the resulting sub-
groups with genes linked to distinct stages of B-cell differ-
entiation. That SPIBhigh/BATFlow-ABC-DLBCL is more
signiicantly associated with genes expressed in resting B-
cells is generally consistent with what is known of the nor-
mal function and expression pattern of SPIB which has
previously been identiied as a regulator of B-cell signal-
ing pathways and a repressor of plasma cell differentiation
(10–13). Furthermore, the signiicant enrichment of genes
on chr19 in the vicinity of SPIB, including genes previously
identiied as coordinately overexpressed in ABC-DLBCLs
with ampliication of chr19 by Lenz et al. (14), is consistent
with chr19 ampliication providing a pathogenetic mecha-
nism in the SPIBhigh/BATFlow-ABC-DLBCL subgroup. In
contrast, the enrichment in the SPIBlow/BATFhigh-ABC-
DLBCL meta-proile of genes expressed in B-cells fol-
lowing IL21 and CD40L activation, STAT3-high ABC-
DLBCL and NFB and CD40 activation, points to com-
bined activation of the STAT3 and CD40/NFB path-
ways as likely mechanisms driving this subgroup. That
SPIBlow/BATFhigh-ABC-DLBCL does not simply relect a
surrogate for STAT3 activation alone is indicated by the
lack of enrichment of two signatures recently described
as predictors of STAT3 activation in DLBCL as a whole
(61). BATF has been previously identiied as a target of the
NFB and STAT3 pathways in other cell systems (73–76),
while IRF4 is seen as a principle target of NFB activity in
B-cell differentiation (77). In T-cells BATF and IRF4 coop-
erate with STAT3 acting potentially as pioneer factors (18).
These transcription factors are thus likely to provide impor-
tant hubs for signal integration both in post-germinal cen-
tre B-cell neoplasia and at the initiation of B-cell terminal
differentiation.
From the point of view of clinical signiicance we have
shown here that a high expression of SPIB and low ex-
pression BATF mRNA can identify a good prognostic
group of DLBCL when treated with currently standard im-
munochemotherapy, R-CHOP.While this association could
be observed in two of the existing data sets of R-CHOP
treated DLBCL including the largest data set generated
from fresh-frozen samples by the LLMPP (GSE10846)
(29), and our population based cohort (GSE32918), it was
not reproduced in the data set generated by The Inter-
national DLBCL Rituximab-CHOP Consortium Program
(GSE31312) (37). The latter includes the largest number of
R-CHOP treated DLBCL cases analysed by gene expres-
sion proiling to date, and was generated on the same plat-
form as the LLMPP data set, GSE10846, but derives from
formalin-ixed parafin embedded rather than fresh frozen
samples. The reason why a good outcome group of ABC-
DLBCL could not be identiied from relative SPIB and
BATF mRNA expression in GSE31312 could not be ascer-
tained from the gene expression data, but it may relect un-
derlying differences in case selection. In this regard, it is no-
table that our data set GSE32918 is unique in representing
the general population of DLBCL from a single geograph-
ically deined area (62), while other data sets derive from
multi-institutional research consortia.
That SPIBlow/BATFhigh-ABC-DLBCL is signiicantly
associated with mutation of MYD88 is consistent with
the model recently proposed by Yang et al. of a role for
SPIB/IRF4 heterodimers in repressing autocrine IFN se-
cretion that limits ABC-DLBCL survival (16). In this re-
gard, a striking feature of our results is the inding that
in our population-based patient cohort SPIBhigh/BATFlow-
ABC-DLBCLs with aMYD88-L265P mutation, detectable
by Sanger sequencing, identiies a distinct group of ABC-
DLBCL with a favourable outcome on current therapy. In-
deed, the outcome of this small subgroup might be consid-
ered to represent ‘cure’. SinceMYD88-L265Pmutation sta-
tus andmRNA expression levels are readily determined in a
clinical setting it will be important to extend these observa-
tions in future, and evaluate whether this combination can
be used to prospectively identify a subset of good risk ABC-
DLBCL cases. However, we stress that given the small pa-
tient number in the retrospective analysis presented here, the
result is at present only suggestive.
The signiicant association of SPIB expression with
MYD88 mutation status may also link to recent data
demonstrating that MYD88-L265P remains dependent on
TLRs in order to manifest its oncogenic potential (65). Fur-
ther to this in a recent elegant study the impact of MYD88-
L265P has been examined inmurine models, demonstrating
that the oncogenic potential of MYD88-L265P is also con-
strained by feedback mechanisms restricting NFB path-
way activation and by induction of apoptosis (66). SPIB
is part of the core transcriptional network of plasmacytoid
dendritic cells (48,78,79), which are particularly specialized
for cellular responses following TLR ligation (80). Consis-
tent with this extensive occupancy of SPIB in the promot-
ers and immediate vicinity of TLR4, TLR7 and TLR9 as
well as MYD88 itself was evident from ChIP-seq data in
OCI-LY3 and LY10 cells. While signiicant effects on TLR
andMYD88mRNA expression were not observed on SPIB
knockdown, this could be explained by the transient na-
ture of SPIB knockdown in our experiments, and the poten-
tial for redundant regulatory input from other transcription
factors. A particularly intriguing possibility is suggested by
the preferential expression of TCF4 (also known as E2–2)
in the SPIBhigh/BATFlow-ABC-DLBCL subgroup, and the
presence of several SPIB binding peaks across the TCF4
(E2–2) locus in OCI-LY3 and LY10 cells. Given the impor-
tance of E2–2 and SPIB in plasmacytoid dendritic cell de-
velopment (48,79), these observations suggest that cooper-
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ation between these factors may contribute to the biology
of the SPIBhigh/BATFlow-ABC-DLBCL.
In conclusion, the data presented here deine the relation-
ship of IRF4 to its endogenous partners in ABC-DLBCL
cell lines identifying BATF as a principle IRF4 partner in
addition to SPIB in these models of lymphoma. Our data
also indicate that a predominant input from SPIB correlates
with a speciic subgroup of primary ABC-DLBCL signii-
cantly associated withMYD88mutation and a better prog-
nosis in the context of currently standard therapy. These
data support a model in which overriding input from SPIB
is not a unifying feature of ABC-DLBCL, but instead con-
tributes to heterogeneity in this subset. Our indings iden-
tify disease heterogeneity in ABC-DLBCL intimately asso-
ciated with the gene regulatory network controlling the ini-
tiation of plasma cell differentiation and the activated B-cell
program.
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